|
Leading innovative, commercial-stage global biotech company Antengene Corporation Limited announced that it will present the first preclinical data on ATG-207 (aCD3-TGF-ß bifunctional fusion protein) in a poster presentation at the 2026 European Congress of Rheumatology (EULAR 2026), taking place from June 3 to 6 at Excel London in the United Kingdom.
ATG-207 represents Antengene's first disclosed program from its T cell-mediated autoimmune disease research efforts.
T cell-mediated autoimmune diseases are characterized by sustained activation of pathogenic effector T cells and insufficient or unstable regulatory T cell function, resulting in an inability to establish durable immune tolerance. These diseases remain an area of significant unmet medical need, as existing anti-inflammatory therapies may not sufficiently eliminate persistent pathogenic effector T cells or restore long-term immune balance.
ATG-207 is designed to address these challenges through a differentiated dual mechanism that integrates CD3-mediated T cell modulation with localized, TGFßRIII-biased TGF-ß activity, with the goal of selectively suppressing pathogenic T cells while promoting regulatory T cell induction and immune tolerance.
The abstract selected for poster presentation at EULAR 2026 describes preclinical studies evaluating ATG-207’s receptor binding, T cell receptor modulation, regulatory T cell induction, cytokine release profile and in vivo activity in models of T cell-mediated autoimmune disease.
In these studies, ATG-207 showed preferential binding to TGFßRIII, downregulated surface T cell receptor expression, induced regulatory T cells in vitro and demonstrated therapeutic efficacy through a mouse surrogate molecule in an experimental autoimmune encephalomyelitis model.
Compared with an unbiased aCD3-TGF-ß fusion protein control, ATG-207 or its mouse surrogate induced substantially lower levels of proinflammatory cytokine release in human whole blood assays and in mice.
Antengene is into developing and commercializing first-in-class and/or best-in-class medicines for autoimmune diseases, solid tumours and haematological malignancies indications.
The company's pipeline spans from preclinical to commercial stages, with key investigational candidates including ATG-022 (CLDN18.2 ADC), ATG-037 (oral CD73 inhibitor), ATG-101 (PD-L1 x 4-1BB bispecific antibody), ATG-125 (B7-H3 × PD-L1 bispecific ADC), ATG-207 (aCD3-TGF-ß bifunctional fusion protein), as well as T cell engager (TCE) programs developed using Antengene’s proprietary AnTenGager platform.
|